Cost-effectiveness of adjuvant docetaxel for node-positive breast cancer patients: Results of the PACS 01 economic study

Annals of Oncology

Volumn 21, Issue 7, 2009, Pages 1448-1454

  Marino, P ^a,b   Siani, C ^c   Roche H ^d   Protiere C ^a,b   Fumoleau, P ^e   Spielmann, M ^f   Martin, A L ^g   Viens, P ^h   Le Corroller Soriano, A G ^a,b  

^a Inst Natl S de la Rech M   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c UNIVERSITÉ LYON 1   (France)

^d INSTITUT CLAUDIUS REGAUD   (France)

^e CENTRE GEORGES FRANÇOIS LECLERC   (France)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g FNCLCC   (France)

^h INSTITUT PAOLI CALMETTES   (France)

Author keywords

Breast cancer; Cost effectiveness; Taxanes; Uncertainty

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE FREE SURVIVAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; LYMPH NODES; MIDDLE AGED; MODELS, ECONOMIC; NEOPLASM METASTASIS; NEOPLASM STAGING; QUALITY-ADJUSTED LIFE YEARS; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 77954248744     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp561     Document Type: Article

References (27)

1. Willett WC, Rockhill B, Hankinson SE et al. Epidemiology and nongenetic causes of breast cancer. In Harris JR, Lippman ME, Morrow M, Osborne CK (eds), Disease of the Breast. Philadelphia, PA: Lippincott Williams & Wilkins 2000; 175-2
2. Bonneterre J, Roche H, Kerbrat P et al. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2005; 23: 2686-26
3. Chevallier B, Fumoleau P, Kerbrat P et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1995; 13: 314-3
4. Ravdin PM, Burris HA III, Cook G et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995; 13: 2879-28
5. Valero V, Holmes FA, Walters RS et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracyclineresistant metastatic breast cancer. J Clin Oncol 1995; 13: 2886-2894
6. Henderson IC, Berry DA, Demetri GD et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21: 976-983
7. Mamounas EP, Bryant J, Lembersky B et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005; 23: 3686-3696
8. Martin M, Pienkowski T, Mackey J et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352: 2302-2313
9. Marino P. Measuring the cost of chemotherapy is important, but it is not enough. Ann Oncol 2008; 19: 409-410
10. Roche H, Fumoleau P, Spielmann M et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 2006; 24: 5664-5671
11. Willan A, Briggs A. The Statistical Analysis of Cost-effectiveness Data. Chichester, UK: John Wiley & Sons 2006
12. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000; 38: 583-637
13. Cocquyt V, Moeremans K, Annemans L et al. Long-term medical costs of postmenopausal breast cancer therapy. Ann Oncol 2003; 14: 1057-1063
14. de Peretti C, Siani C. Decision-making with the incremental cost-effectiveness ratio under uncertainty. Health Syst Sci 2006; 9(1-2): 111-145
15. Siani C, de Peretti C. Fieller's method performance in problematic cases for decision-making. Health Syst Sci 2006; 9(1-2): 205-226
16. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004; 13: 437-452
17. Eichler HG, Kong SX, Gerth WC et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004; 7: 518-528
18. Hirth RA, Chernew ME, Miller E et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000; 20: 332-342
19. Raftery J. NICE: faster access to modern treatments? Analysis of guidance on health technologies. BMJ 2001; 323: 1300-1303
20. Garber AM. Advances in cost-effectiveness analysis of health interventions. In Culyer AJ, Newhouse JP (eds), Handbook of Health Economics. edition 1, volume 1, chapter Amsterdam, The Netherlands: North Holland 2000; 181-221
21. Owens DK. Interpretation of cost-effectiveness analyses. J Gen Intern Med 1998; 13: 716-717
22. Weinstein M. From cost effectiveness ratios to resource allocation: where to draw the line? In Sloan FA (ed.), Valuing Health Care: Costs, Benefits & Effectiveness of Pharmaceuticals and Other Medical Technologies. Cambridge: Cambridge University Press 1995; 77-97
23. Au HJ, Golmohammadi K, Younis T et al. Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects. Breast Cancer Res Treat 2009; 114(3): 579-587
24. Wolowacz SE, Cameron DA, Tate HC, Bagust A. Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis. J Clin Oncol 2008; 26: 925-933
25. Younis T, Rayson D, Sellon M, Skedgel C. Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 1Breast Cancer Res Treat 2008; 111: 261-267
26. Ward S, Simpson E, Davis S et al. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation. Health Technol Assess 2007; 11: 1-144
27. Marsh S. Pharmacogenomics. Ann Oncol 2007; 18 (Suppl 9): ix24-ix28